It starts with a simple assumption: strip every medical word from a herbal patch, inhaler, or roll-on stick, and it automatically becomes a cosmetic. Yet, this quiet shortcut is the single most common mistake Product Registration Indonesia (PRI) encounters. Indonesia’s Food and Drug Authority (Badan Pengawas Obat dan Makanan / BPOM) looks far beyond the words on a label.
Text is only one piece of the puzzle. In BPOM herbal classification, the authority evaluates the total presentation: formula, dosage form, instructions, and visual branding, all read together.
PRI saw this firsthand during an assessment of four patch and inhaler SKUs from a GMP-certified manufacturer. The team had removed every medical claim from the packaging, expecting a smooth path into the cosmetic category. But because the dosage form and formula told a different story, no amount of copy editing could change the regulatory outcome.
For brand owners, manufacturers, and distributors bringing topical herbal products into Indonesia, understanding this distinction is crucial. This article breaks down the three pathways your product is likely to face, and reveals the critical weak points to review before submitting your first filing.
What Is BPOM Herbal Classification?
The Short Answer
BPOM herbal classification is the decision on whether a herbal product is registered as a cosmetic, a quasi-drug (obat kuasi) or a natural medicine (obat bahan alam, or OBA). BPOM reaches it by reading formula, dosage form, instructions and artwork together, not by claim wording alone.
A cosmetic is limited to cleaning, perfuming, altering appearance or keeping the body in good condition, with no treatment claim. A quasi-drug carries an active ingredient with a local, non-systemic effect for minor complaints. A natural medicine is a natural-ingredient preparation positioned as a medicine.
The Three Pathways at a Glance
| Pathway | What it covers | Main regulation | Typical signals |
|---|---|---|---|
| Cosmetic (kosmetika) | External use to clean, perfume, change appearance or maintain the body; no treatment claim | Peraturan BPOM Nomor 21 Tahun 2022; Nomor 17 Tahun 2023 | No active ingredient with a pharmacological action; care or beauty purpose |
| Quasi-drug (obat kuasi) | Active ingredient with a local, non-systemic effect for minor complaints | Peraturan BPOM Nomor 7 Tahun 2023; labelling under Nomor 10 Tahun 2024 | Counter-irritants, balms, medicated patches, inhalant oils |
| Traditional medicine (OBA) | Natural-ingredient preparation positioned as a medicine | Peraturan BPOM Nomor 25 Tahun 2023 | Medicine positioning outside the quasi-drug definition |
For a wider view of how BPOM separates cosmetics from quasi-drugs, see PRI’s guide to product category in Indonesia. Herbal products that do stay cosmetic are covered in how traditional cosmetics are registered.
Why Wording Alone Cannot Change BPOM Product Classification
Many brands treat classification as an editing task. They strip words such as relieves, treats or therapeutic and expect a cosmetic result. In PRI’s experience, reviewers start somewhere else: what the product is, how it acts and what the pack tells the user to do with it.
Formula: Ingredients With a Recognised Pharmacological Action
Some natural ingredients are counter-irritants, meaning they create a warming or cooling sensation that distracts from minor pain. In the four-SKU assessment, the warming patches carried capsicum and cassia oils, and the cooling patch carried peppermint oil. All three have a recognised pharmacological action.
A recognised action in the formula points toward the quasi-drug definition in Peraturan BPOM Nomor 7 Tahun 2023, issued by BPOM. Marketing language cannot remove an active ingredient from the formula, which is why composition tends to anchor the decision.
Dosage Form and Instructions: Where and How the Product Is Used
An inhaler and a roll-on stick in the same assessment combined menthol, camphor and borneol. The artwork showed the stick applied to the temple, which reads as a local-effect use, not a beauty routine.
The label also carried a contraindication for people with G6PD deficiency (glucose-6-phosphate dehydrogenase deficiency, an inherited enzyme condition). A contraindication is itself a pharmacological safety warning, and in PRI’s experience cosmetic labels rarely need one.
Artwork: Images Carry Claims Too
The artwork in that assessment showed an anatomical spine and knee with marked pain zones, plus the words “instant relief”. Reviewers read that as a musculoskeletal claim, whatever the written text says.
This is the point most brands miss. A claims list can be clean while the graphics still make the claim. Every panel, diagram and icon should be treated as part of the claim set and reviewed together with the text.
Case Study: What Decided Four Herbal Topical SKUs
The table summarises what decided the outcome for the four SKUs. Each row is a signal a reviewer could read straight from the product file, and none of them depended on a single claim sentence.
| Signal | What the file showed | Why it mattered |
|---|---|---|
| Warming patches | Capsicum and cassia oils | Counter-irritants with a recognised pharmacological action |
| Cooling patch | Peppermint oil | The same type of action in a cooling form |
| Inhaler and roll-on stick | Menthol, camphor and borneol, applied to the temple | Local-effect use shown on the pack |
| Safety warning | G6PD deficiency contraindication | A pharmacological safety warning |
| Artwork | Anatomical spine and knee, pain zones, “instant relief” | Read as a musculoskeletal claim |
The result was the same for all four SKUs: no rewording could move them into cosmetics. The open question became which non-cosmetic pathway fitted, and that belongs in a documented classification review before any filing begins.
Document Gaps That Fail a File Before Classification Matters
The same file showed a second pattern. The documents failed before classification mattered. In PRI’s experience, a file whose papers disagree with each other rarely reaches the classification debate at all.
- One SKU was missing from the Certificate of Free Sale (CFS), the document showing that a product may be sold freely in its country of origin.
- The CFS named one manufacturer, while the artwork named two other manufacturers.
- The GMP certificate carried a different street number from the address printed on the label.
- No GMP evidence existed for the secondary manufacturers named on the pack.
Each gap is small and avoidable. Together they show why a document cross-check belongs before the artwork is printed. PRI’s article on the PerBPOM 27/2025 facility audit explains how BPOM verifiers treat facility evidence.
Legal Basis: Which Regulation Governs Which Pathway
Each pathway sits under a different regulation. The table lists those that matter most for topical herbal products..
| Topic | Regulation | Issuing body |
|---|---|---|
| Quasi-drug definition | Peraturan BPOM Nomor 7 Tahun 2023 | BPOM |
| Labelling of natural medicine, quasi-drugs and supplements | Peraturan BPOM Nomor 10 Tahun 2024 tentang Penandaan Obat Bahan Alam, Obat Kuasi, dan Suplemen Kesehatan | BPOM |
| Cosmetic notification | Peraturan BPOM Nomor 21 Tahun 2022 (procedure) and Nomor 17 Tahun 2023 (product information document) | BPOM |
| Natural medicine | Peraturan BPOM Nomor 25 Tahun 2023 | BPOM |
| Pharmaceutical-grade ingredients in certain dosage forms | Peraturan BPOM Nomor 26 Tahun 2025, in force 3 October 2025 | BPOM |
| Halal product assurance | Peraturan Pemerintah (PP) Nomor 42 Tahun 2024 | Government of Indonesia |
Quasi Medicine Registration in Indonesia: What Follows Classification
Once a product sits in the quasi-drug pathway, three topics shape the BPOM registration filing: labelling, ingredient grade and halal status. PRI’s Quasi Medicine Registration in Indonesia support covers classification, dossier preparation and BPOM liaison for these steps.
Labelling Under PerBPOM 10/2024
Peraturan BPOM Nomor 10 Tahun 2024 governs the labelling of natural medicine, quasi-drugs and health supplements. Artwork prepared for a cosmetic launch therefore cannot simply be reused, because the label itself is part of what BPOM assesses.
Ingredient Grade Under PerBPOM 26/2025
Peraturan BPOM Nomor 26 Tahun 2025, in force since 3 October 2025, requires ingredients in certain dosage forms to meet pharmaceutical-grade standards. Whether a given patch or inhaler is caught should be checked against the regulation with an adviser.
Halal Certification in Indonesia: Extended
Under Peraturan Pemerintah (PP) Nomor 42 Tahun 2024, halal certification becomes mandatory on 18 October 2026 for natural medicine, quasi-drugs, health supplements and cosmetics. However, according to Government Press Release No. HM.02.04/361/SET.M.EKON.3/10/2026, the government officially adjusted the phased implementation schedule for mandatory halal certification through amendments to Government Regulation (PP) Number 42 of 2024. This revision adjusts the compliance deadline for mandatory halal certification for natural medicines, quasi-drugs, health supplements, and cosmetics to October 17, 2028.
To understand how the revised timeline affects your products, read the analysis in the article, “Indonesia Halal Deadline 2028: What the New Schedule Means for Your Products,” below:
In PRI’s experience, halal planning runs most smoothly when it starts alongside classification, because ingredient and manufacturer documents overlap. Each product’s status should be confirmed before launch.
A Four-Question Order for Screening a Topical Herbal Product
PRI screens a product in a fixed order. The sequence is an orientation tool, not a determination. A classification should be confirmed against the full formula, artwork and documents by a regulatory adviser.
- Does any active ingredient have a pharmacological action?
- Is the effect local and aimed at a minor complaint?
- Does any panel show therapeutic imagery or a contraindication?
- Who will hold the registration in Indonesia?
| Answer pattern | What it suggests |
|---|---|
| No pharmacologically active ingredient, and no therapeutic imagery or contraindication | Cosmetic notification may be worth reviewing |
| Active ingredient, local effect, minor complaint | Quasi-drug pathway is likely |
| Active ingredient, with an effect or claim beyond local and minor | Natural medicine or another pathway needs assessment |
| Therapeutic imagery or contraindication on a product positioned as cosmetic | Mismatch; the presentation is likely to be read as non-cosmetic |
Who Will Hold the Registration? Three Options
The fourth question is commercial, not technical. Registration is filed through an eligible party in Indonesia, and the choice affects later flexibility. Brand owners can compare three common options below.
| Option | How it works | Points to weigh |
|---|---|---|
| Local distributor | The distributor files and holds the registration | Simple to start; in PRI’s experience the approval can become tied to that distributor |
| Licence holder | An independent licensed company holds the registration for the brand | Allows a change of distributor later; depends on a reliable holder |
| Own Indonesian company | The brand sets up a local entity to hold it | Full control; the entity and its licensing must exist first |
Key Acronyms in This Article
- BPOM: Badan Pengawas Obat dan Makanan, Indonesia’s Food and Drug Authority.
- PerBPOM: Peraturan BPOM, a regulation issued by BPOM.
- PP: Peraturan Pemerintah, a Government Regulation.
- OBA: Obat Bahan Alam, natural medicine or traditional medicine.
- SKU: stock keeping unit, an individual product variant.
- GMP: Good Manufacturing Practice.
- CFS: Certificate of Free Sale.
- G6PD: glucose-6-phosphate dehydrogenase, an enzyme whose deficiency is an inherited condition.
- JDIH: Jaringan Dokumentasi dan Informasi Hukum, the legal documentation network.
Your Next Step Toward a Confident Launch
A herbal patch, inhaler or roll-on stick can reach the Indonesian market well, provided it is registered under the pathway BPOM will actually recognise. Decisions made early, before artwork is printed and certificates are issued, are the ones that protect a launch.
Product Registration Indonesia (PRI) supports international manufacturers with product classification, dossier preparation, label and artwork review and BPOM liaison. That early review catches mismatched claims, images and documents before they turn into rejections.
Brand owners with a topical herbal product can reach PRI by filling out the form below to have their formula, artwork, and documents reviewed together.
